Sierra Oncology Inc SRRA.O :
* SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM
* SIERRA ONCOLOGY INC - ADDING NEW SRA737 MONOTHERAPY COHORT FOR CCNE1-DRIVEN OVARIAN CANCER
* SIERRA ONCOLOGY INC - SRA141 IND SUBMISSION PLANNED IN H2 2018
* SIERRA ONCOLOGY - ONGOING SRA737 CLINICAL STUDIES EXPANDED TO TARGET AGGREGATE ENROLLMENT OF 200 PATIENTS ACROSS TEN CANCER INDICATIONS
* SIERRA ONCOLOGY - TO INITIATE PHASE 1B/2 TRIAL IN Q4 TO EVALUATE SRA737 WITH ZEJULA TO TREAT METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
* SIERRA ONCOLOGY - EXPANDING NUMBER OF ACTIVE SITES RECRUITING PATIENTS INTO SRA737-01 PHASE 1/2 MONOTHERAPY TRIAL FROM 3 TO 15
* SIERRA ONCOLOGY - MAJORITY OF REPORTED ADVERSE EVENTS IN SRA737-02 PHASE 1/2 LDG COMBINATION TRIAL HAVE BEEN GRADE 1 OR GRADE 2 IN SEVERITY
* SIERRA ONCOLOGY - ONLY ONE GRADE 3 TREATMENT RELATED AE (NEUTROPENIA) WAS OBSERVED, AT 40 MG SRA737/300 MG/M(2) GEMCITABINE